Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Committee Closes Books On 2016 Pricing Investigation; PBMs In Hot Seat Next?

Executive Summary

US Senate Aging Committee wrapped up its investigation into price spikes for off-patent drugs with some relatively unsurprising (and – for most innovator companies – unthreatening) policy recommendations; a brief coda to the report offers two possible directions for future investigations: abuse of the patent system – or the impact of PBM practices.


Related Content

Drug Pricing ‘Biggest Offenders’ Are Annual Increases On Widely Used Brands
Drug Affordability Review By National Academies Kicks Off With Lower Profile Than Expected
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
Congress Already Impacting Industry Drug Pricing Abuses, Valeant Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts